Five-fraction MR-guided prostate-bed radiotherapy showed low early toxicity
No grade 3 toxicity occurred after five-fraction MR-guided salvage radiotherapy, while urinary and bowel quality-of-life scores remained stable.
Tag
prostate
Prostate radiotherapy modestly increased secondary pelvic cancer incidence over long follow-up
Randomized evidence suggested a 4.5-point increase in second-cancer incidence, while excess mortality from other cancers was substantially smaller.
AutoAdapt produced acceptable prostate MR-guided plans with minimal planner input
AI-generated constraints produced clinically acceptable adaptive prostate plans, although only seven of ten met every prespecified planning objective.
Prostate focal boost review defines MRI-based contouring and isotoxic planning
MRI-defined biopsy-confirmed lesions can be boosted safely when robust image guidance and normal-tissue constraints take priority over complete boost coverage.
ESTRO defined minimum standards for prostate SBRT implementation
ESTRO recommends prostate SBRT for selected intermediate-risk disease with MRI-based contouring, rigorous quality assurance, and daily image guidance.
Five-fraction prostate SBRT showed low severe toxicity across Austrian centres
Linac-based 40 Gy in five fractions produced low severe toxicity and rapid urinary recovery across seven centres, although follow-up remained short.
Biopsy localization uncertainty substantially altered HDR prostate brachytherapy dose estimates
Millimeter-scale localization uncertainty shifted assigned biopsy doses by several Gy and made nominal DVH threshold classification frequently unreliable.
PROTEUS improved composite MFS but not conventional imaging-defined MFS
Perioperative apalutamide improved pathological response and composite MFS, but not conventional imaging-defined MFS, raising concern about overtreatment in broadly defined high-risk disease.
Prolonged first-generation antiandrogens showed no survival benefit with prostate radiotherapy
Extending first-generation antiandrogen therapy beyond short-term use was not associated with better survival and may increase early ADT discontinuation.
Five-fraction prostate radiotherapy showed low severe toxicity in men aged 75 or older
Five-fraction prostate radiotherapy achieved 82% three-year biochemical control with very few grade 3 toxicities in men aged 75 or older.
Prostate SABR practice varied despite broad adoption across Australia and New Zealand
Most surveyed oncologists offered prostate SABR, but patient selection, target volumes, focal boosts and access to supporting technology varied.
Hydrogel spacers reduced invasive treatment for radiation proctitis after prostate radiotherapy
Hydrogel spacer placement was associated with a 74% lower risk of gastrointestinal endoscopic hemostasis after prostate radiotherapy.
Daily adaptation improved target coverage and rectal sparing in postoperative prostate radiotherapy
Daily adaptation increased prostate-bed coverage from 92.1% to 98.5% and reduced high-dose rectal exposure during hypofractionated salvage radiotherapy.
Five-fraction prostate radiotherapy reduced estimated carbon emissions by 59%
Five-fraction prostate radiotherapy produced 58.6% lower estimated carbon emissions than a 26-fraction schedule, mainly by reducing patient travel.
Two-fraction HDR brachytherapy achieved durable control in favourable-risk prostate cancer
High-dose-rate brachytherapy using 13.5 Gy twice achieved 81.6% ten-year biochemical control with limited late genitourinary toxicity.